Pharma Stocks

Is It Too Late To Consider Merck (MRK) After A 48% One-Year Gain?

This article examines whether Merck, at around US$113 per share, still offers value or if most of the upside is…

Read More »

Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story

FDA approves VEPPANU (vepdegestrant), co developed by Arvinas and Pfizer, as the first PROTAC protein degrader therapy for advanced ER+/HER2,…

Read More »

Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Pullback

Event overview and recent stock context Agios Pharmaceuticals (AGIO) has drawn attention after a recent share price pullback, with the…

Read More »

A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News

Indivior Pharmaceuticals (INDV) is back on investors’ radars after a busy stretch that combined strong Q1 2026 results, a raised…

Read More »

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

Healthcare royalties company Royalty Pharma (NASDAQ: RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should…

Read More »

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress

Crinetics Pharmaceuticals (CRNX) has been in focus after the European Commission approved PALSONIFY, its once daily oral treatment for acromegaly,…

Read More »

How Investors Are Reacting To Eisai (TSE:4523) Leaning On Leqembi After Fresh Sales Update

Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s…

Read More »

Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma

Over the last year, a good number of insiders have significantly increased their holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT). This…

Read More »

Piramal Pharma Ltd Reports Flat Quarterly Financial Trend…

Quarterly Financial Performance Overview In the quarter ended March 2026, Piramal Pharma posted net sales of ₹2,751.77 crores, marking a…

Read More »

3 ASX Penny Stocks With Over A$90M Market Cap

The Australian share market is experiencing a challenging period, with a recent downturn marking its seventh consecutive day of declines.…

Read More »